Shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) shot up 5.3% during trading on Monday . The company traded as high as $72.48 and last traded at $71.69, with a volume of 630,413 shares traded. The stock had previously closed at $68.08.

Several equities analysts have recently issued reports on ALNY shares. Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, April 17th. Zacks Investment Research cut Alnylam Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Thursday, May 5th. Needham & Company LLC reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, May 4th. Leerink Swann reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Finally, Credit Suisse Group AG reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $117.82.

The stock’s market capitalization is $6.14 billion. The company has a 50 day moving average of $61.21 and a 200-day moving average of $63.62.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.16. The business had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $7.79 million. During the same period in the prior year, the firm earned ($0.62) earnings per share. The business’s revenue for the quarter was down 60.4% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals Inc. will post ($4.94) earnings per share for the current year.

In other news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several hedge funds recently made changes to their positions in ALNY. Sei Investments Co. boosted its stake in shares of Alnylam Pharmaceuticals by 493.7% in the fourth quarter. Sei Investments Co. now owns 19,569 shares of the biopharmaceutical company’s stock valued at $1,842,000 after buying an additional 16,273 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 0.4% in the fourth quarter. Mutual of America Capital Management LLC now owns 21,637 shares of the biopharmaceutical company’s stock valued at $2,037,000 after buying an additional 87 shares in the last quarter. Gulf International Bank UK Ltd boosted its stake in shares of Alnylam Pharmaceuticals by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 23,100 shares of the biopharmaceutical company’s stock valued at $2,175,000 after buying an additional 220 shares in the last quarter. Advisors Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the fourth quarter. Advisors Asset Management Inc. now owns 64,827 shares of the biopharmaceutical company’s stock valued at $6,103,000 after buying an additional 226 shares in the last quarter. Finally, BlackRock Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 8.2% in the fourth quarter. BlackRock Advisors LLC now owns 179,529 shares of the biopharmaceutical company’s stock valued at $16,901,000 after buying an additional 13,612 shares in the last quarter.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.